Cover Image

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use

Abstract: Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer. Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of...

Full description

Saved in:

Bibliographic Details
Main Authors:	C. García-Muñoz (Author), S. Cortijo-Cascajares (Author), I. Cañamares-Orbis (Author), M. P. Goyache-Goñi (Author), J. M. Ferrari-Piquero (Author)
Format:	Book
Published:	Elsevier, 2014-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atención farmacéutica especializada en los servicios de urgencias hospitalarios
by: I. Cañamares Orbis, et al.
Published: (2013)

Atención farmacéutica especializada en los servicios de urgencias hospitalarios
by: I. Cañamares Orbis, et al.
Published: (2013)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
by: Min Ye, et al.
Published: (2021)

Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
by: Elia Romero Carreño, et al.
Published: (2016)

Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors
by: Arba Karcini, et al.
Published: (2024)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
by: Antonio Fernando Leis-Filho, et al.
Published: (2021)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018)

Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment
by: Sahar Eljack, et al.
Published: (2022)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
by: A. Geneste, et al.
Published: (2020)

Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
by: Shengnan Bao, et al.
Published: (2020)

Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone
by: I. Gómez Valbuena, et al.
Published: (2014)

Cuidado Farmacêutico a pacientes em tratamento com Herceptin® (Transtuzumabe): um estudo de caso
by: Juliana dos Santos SILVA, et al.
Published: (2020)

Cytotoxic Effect of Paclitaxel and Lapatinib <i>Co</i>-Delivered in Polylactide-<i>co</i>-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells
by: Alicja Zajdel, et al.
Published: (2019)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
by: Chembolli Lakshmi, et al.
Published: (2010)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023)

Brachioradial pruritus in a patient with metastatic breast cancer to her cervical spine
by: Christine Pham, BS, et al.
Published: (2020)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023)

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study
by: Raffaella Palumbo, et al.
Published: (2024)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021)

Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine
by: Hua Xing, et al.
Published: (2018)

Different chemical proteomic approaches to identify the targets of lapatinib
by: Tatjana Kovačević, et al.
Published: (2023)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
by: Xiuwen Guan, et al.
Published: (2023)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
by: Hongmei Dong, et al.
Published: (2022)

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016
by: M. Spanggaard, et al.
Published: (2022)

Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
by: Marija Križić, et al.
Published: (2024)

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: N. A. Kozyavin, et al.
Published: (2018)

HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
by: Rosalba Torrisi, et al.
Published: (2023)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023)

Personality Plus: Some Experiences of Emma McChesney and Her Son, Jock
by: Ferber, Edna, 1885-1968; Flagg, James Montgomery, 1877-1960 [Illustrator]

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
by: Mashan L. Abdullah, et al.
Published: (2018)

Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019)

Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives
by: Ahmed Elkamhawy, et al.
Published: (2022)

A single centre, real world experience of T-DM1 in the treatment of HER2-positive metastatic breast cancer patients in India
by: Vindhya Vasini, et al.
Published: (2024)